What Is Akari Therapeutics Plc (AKTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Akari Therapeutics Plc's intrinsic value is estimated at a composite fair value of $8.18. Trading at $12.07, the stock is approaching fair value or slight overvaluation (implied return of -32.3%), as 5 of 7 models suggest limited further upside. The most optimistic model, Sentiment SOTP, places fair value at $14.94 (+23.8%), while ML-RIV — the most conservative — estimates $2.26 (-81.3%). This +105.0% gap reflects genuine analytical uncertainty about Akari Therapeutics Plc's intrinsic worth.
What Do the Models Say About AKTX?
7 of 13 models are currently active for AKTX. Of these, 1 model suggests upside while 6 models suggest overvaluation. The Bayesian DCF estimates AKTX's intrinsic value at $2.67, implying -77.9% downside from the current price. See which stocks rank higher →
How Does AKTX Rank in Biotechnology?
Among 76 Biotechnology stocks, AKTX ranks #69 by Quality of Company score. CirclFi's QOC score of 2.4/10 evaluates 32 fundamental signals. A score of 2.4 signals below-average fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Akari Therapeutics Plc, metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is AKTX a Value Trap?
CirclFi's Value Trap algorithm assigns AKTX a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Akari Therapeutics Plc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Akari Therapeutics Plc scores 2.4 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +105.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AKTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AKTX's 7 active models, average confidence is 13%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad